2. Mistry PK, Cappellini MD, Lukina E, et al. 2011; A reappraisal of Gaucher disease-diagnosis and disease management algorithms. Am J Hematol. 86:110–5. DOI:
10.1002/ajh.21888. PMID:
21080341. PMCID:
PMC3058841.
Article
3. Kaplan P, Baris H, De Meirleir L, et al. 2013; Revised recommendations for the management of Gaucher disease in children. Eur J Pediatr. 172:447–58. DOI:
10.1007/s00431-012-1771-z. PMID:
22772880.
Article
7. Thomas AS, Mehta AB, Hughes DA. 2013; Diagnosing Gaucher disease: an on-going need for increased awareness amongst haematologists. Blood Cells Mol Dis. 50:212–7. DOI:
10.1016/j.bcmd.2012.11.004. PMID:
23219328.
Article
8. Mistry PK, Sadan S, Yang R, Yee J, Yang M. 2007; Consequences of diagnostic delays in type 1 Gaucher disease: the need for greater awareness among hematologists-oncologists and an opportunity for early diagnosis and intervention. Am J Hematol. 82:697–701. DOI:
10.1002/ajh.20908. PMID:
17492645.
Article
10. Yoo HW, Lee HJ, Kim DS, et al. 2014. Disease Management Guideline on LSD - 2. Gaucher disease. The Korean Society of Inherited Metabolic Disease & Medical Review;Seoul, Korea:
12. Charrow J, Andersson HC, Kaplan P, et al. 2000; The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med. 160:2835–43. DOI:
10.1001/archinte.160.18.2835. PMID:
11025794.
13. Motta I, Filocamo M, Poggiali E, et al. 2016; A multicentre observational study for early diagnosis of Gaucher disease in patients with splenomegaly and/or thrombocytopenia. Eur J Haematol. 96:352–9. DOI:
10.1111/ejh.12596. PMID:
26033455.
Article
14. Marchi G, Nascimbeni F, Motta I, et al. 2020; Hyperferritinemia and diagnosis of type 1 Gaucher disease. Am J Hematol. 95:570–6. DOI:
10.1002/ajh.25752. PMID:
32031266.
Article
15. Diaz GA, Gelb BD, Risch N, et al. 2000; Gaucher disease: the origins of the Ashkenazi Jewish N370S and 84GG acid beta-glucosidase mutations. Am J Hum Genet. 66:1821–32. DOI:
10.1086/302946. PMID:
10777718. PMCID:
PMC1378046.
16. El-Beshlawy A, Tylki-Szymanska A, Vellodi A, et al. 2017; Long-term hematological, visceral, and growth outcomes in children with Gaucher disease type 3 treated with imiglucerase in the International Collaborative Gaucher Group Gaucher Registry. Mol Genet Metab. 120:47–56. DOI:
10.1016/j.ymgme.2016.12.001. PMID:
28040394.
Article
17. Kawame H, Eto Y. 1991; A new glucocerebrosidase-gene missense mutation responsible for neuronopathic Gaucher disease in Japanese patients. Am J Hum Genet. 49:1378–80. PMID:
1840477. PMCID:
PMC1686467.
18. Stirnemann J, Vigan M, Hamroun D, et al. 2012; The French Gaucher's disease registry: clinical characteristics, complications and treatment of 562 patients. Orphanet J Rare Dis. 7:77. DOI:
10.1186/1750-1172-7-77. PMID:
23046562. PMCID:
PMC3526516.
Article
19. Cozzolino I, Picardi M, Pagliuca S, et al. 2016; B-cell non-Hodgkin lymphoma and pseudo-Gaucher cells in a lymph node fine needle aspiration. Cytopathology. 27:134–6. DOI:
10.1111/cyt.12254. PMID:
26033037.
Article
20. Sharma P, Das R, Bansal D, Trehan A. 2015; Congenital dyserythropoietic anemia, type II with SEC23B exon 12 c.1385 A → G mutation, and pseudo-Gaucher cells in two siblings. Hematology. 20:104–7. DOI:
10.1179/1607845414Y.0000000166. PMID:
24801240.
Article
23. Burton BK, Charrow J, Hoganson GE, et al. 2017; Newborn screening for lysosomal storage disorders in Illinois: the initial 15-month experience. J Pediatr. 190:130–5. DOI:
10.1016/j.jpeds.2017.06.048. PMID:
28728811.
Article